Is it a Wise Decision to Invest in Gilead Sciences (GILD)?

ClearBridge Investments, an investment management firm, published its “Sustainability Leaders Strategy” fourth quarter 2021 investor letter – a copy of which can be downloaded here. The ClearBridge Sustainability Leaders Strategy outperformed its Russell 3000 Index benchmark during the fourth quarter. On an absolute basis, the Strategy had gains in nine of 10 sectors in which it was invested (out of 11 sectors total). The main contributors were the IT, consumer discretionary, and health care sectors. The communication services sector was the sole detractor. Spare some time to check the fund’s top 5 holdings to have a clue about their top bets for 2022.

ClearBridge Investments Sustainability Leaders Strategy, in its Q4 2021 investor letter, mentioned Gilead Sciences, Inc. (NASDAQ:GILD) and discussed its stance on the firm. Founded in 1987, Gilead Sciences, Inc. (NASDAQ:GILD) is a Foster City, California-based biotechnology company with a $76.1 billion market capitalization, and is currently spearheaded by its CEO, Daniel O’Day. Gilead Sciences, Inc. (NASDAQ:GILD) delivered a -16.44% return since the beginning of the year, while its 12-month returns are down by -8.39%. The stock closed at $60.67 per share on April 04, 2022.

Here is what ClearBridge Investments Sustainability Leaders Strategy has to say about Gilead Sciences, Inc. (NASDAQ:GILD) in its Q4 2021 investor letter:

“Other pharma companies are providing solutions as well. Biopharmaceutical company Gilead Sciences’ remdesivir, sold under the brand name Veklury, is a broad-spectrum antiviral medication administered by intravenous infusion; it can shorten the time to recovery in hospitalized patients and reduce the risk of hospitalization and death in non-hospitalized patients.”

Our calculations show that Gilead Sciences, Inc. (NASDAQ:GILD) failed to obtain a mark on our list of the 30 Most Popular Stocks Among Hedge Funds. Gilead Sciences, Inc. (NASDAQ:GILD) was in 54 hedge fund portfolios at the end of the fourth quarter of 2021, compared to 55 funds in the previous quarter. Gilead Sciences, Inc. (NASDAQ:GILD) delivered a -15.98% return in the past 3 months.

In December 2021, we also shared another hedge fund’s views on Gilead Sciences, Inc. (NASDAQ:GILD) in another article. You can find other letters from hedge funds and prominent investors on our hedge fund investor letters 2021 Q4 page.

Disclosure: None. This article is originally published at Insider Monkey.